Large Cap Biopharma: January’17 Update-2

2/6/17 1 PM EST Mid-Caps Outperform in 2017

We will update the metrics and performance of “Large Cap Biopharma” after earnings from Gilead Sciences (GILD) and Regeneron (REGN) tomorrow.

  • The XBI is up 11% YTD.
  • The IBB is up 6.3% YTD.
  • Merck (MRK) leads all large cap biotechs up 9.5% YTD.
  • Among mid-caps Incyte (INCY) is up 19% YTD, Seattle Genetics (SGEN) is up 17% YTD, Vertex (VRTX) is up 17% YTD.

=========

Large Cap Biopharmaceuticals: Jan. 2016 Compared to Jan.2017

  • Stock prices are compared for the one year bear market 1/7/16-1/31/17.
  • Financial metrics will be updated after all earnings are reported.
  • Dividends have gone up with stock prices down: ABBV,BMY,AMGN,GILD.
  • Only one stock is up YoY: Celgene (CELG) up 2%.
  • XBI is up 5% YoY; IBB is down 8.6%.
Company Ticker Price Market 2016 P/S PEG Q/Q Q/Q Perform Price 1/18 %Week P 8/11 P/1/31 Div
1/7/2016 Cap $B Rev$B REV EPS %12 mos 2016 JPM’16 2016 2017
8/11/2016 Gr% Gr% 8/11
Abbvie ABBV 57.21 108.5 24.75 4.39 1.17 17.8 17.9 -2.44 57.32 0 66.9 61.11 4.19
Alexion ALXN 174.37 29.73 2.82 10.54 18.4 18.4 -38.8 -29.5 158.68 -9 133.7 130.68
Amgen AMGN 158 129.2 22.2 5.83 2.13 5.9 14.9 0 151.35 -1 172.4 156.68 2.94
Biogen BIIB 284.01 71 11.24 6.32 1.91.9 11.7 21.6 -1.78 273.33 -3.76 314.8 277.24
Bristol Myers BMY 65.27 101.2 17.62 5.74 1.51 17 999 -3.83 62.78 -3.8 61 49.16 3.17
Celgene CELG 111.89 87.3 10.16 8.6 2.16 20.9 72.9 -11.5 103.06 -7.89 113.8 116.15
Gilead Sci GILD 96.25 104.8 32.4 3.24 86.9 -5.7 -11.5 -30.5 91.84 -4.58 79.6 72.45 2.59
Regeneron REGN 501.96 43.8 4.44 9.88 3.46 -31 -9.3 -27.2 462.95 -7.76 421,5 359.29
IBB 304 6.1 -21.1 284.18 -5.93 291.9 278.07
XBI 61.82 1.55 -21.7 61.9 64.9
FBIOX -33.2 191 185
FBT -18.3 98.4 96
No comments yet.

Leave a Reply